Stilla Technologies

Last week our team unveiled the Nio™+ physically at Oxford Global's NextGen Omics conference in London, UK. A booth packed with curious people, and a feedback from our early access users at CHU de Rennes. Couldn't attend live? Watch on-demand here hubs.la/Q028SGfC0

Our first application note on Nio+, released last Friday, is now available. Get access below: hubs.la/Q028Sscv0

It's finally here. Meet Nio+. Automation-friendly. All-in-one. Continuous loading. 7 colors. Capacity of 768. See it here. hubs.la/Q028smgH0

We're just hours away from unveiling the next leap in digital PCR. Last chance to register — secure your spot now! hubs.la/Q0288rHr0

Meet the team at NextGen Omics 2023 and discover the next leap forward in digital PCR, live. Can't attend live? Register via: hubs.ly/Q027_DD_0

Our next product was not created in a vacuum. Listen to the first impressions of innovators across Europe. Register via hubs.la/Q027P2vy0

Next to experts in oncology & digital PCR, our team also gave early access to the team at Exothera. Learn how they experienced our next product on November 10th, register via hubs.la/Q027P2C80

700+ people have registered for us taking the next leap forward in digital PCR. Spanning well over 40 different nationalities across the globe. Do not miss out & register for our product announcement below: hubs.la/Q027v-_j0

Headscratcher. Though not to the trained eye. Discover all about our next product announcement, register today. hubs.la/Q025MDY60

We're collaborating with Europe's leading digital PCR innovators. These past weeks we've collaborated with digital PCR consortium at the University of Ghent. Curious to learn more? Hear all about it during our November 10th announcement hubs.la/Q027b7qM0

We can't w8. Register to our November product announcement. hubs.la/Q025MsZz0

Learn what’s behind #7, register to our product announcement via the link below. hubs.la/Q025MrBJ0

During our early access programme, we're working with leading institutes in oncology, cell and gene therapy as well as digital PCR technology experts. Last week: Centre Eugène Marquis in Rennes, France. Learn about it during our Nov. 10th announcement: hubs.la/Q025QRyW0

The next leap forward in digital PCR. Don't forget to register: hubs.la/Q025Mj2k0

The next leap forward in digital PCR. Register to our November 10th product announcement: hubs.la/Q024NxZB0

Great @biocompare piece on the best uses for dPCR and qPCR. Stilla’s Matthew Grow discusses multiplexed dPCR as a diagnostic complementary to NGS that can allow hospital labs to run more in-house patient testing in place of outsourced or centralized labs: bit.ly/3OVfYbU

For our second installment of #StillaSpotlight, meet Kimberley Gutierrez, PhD, Business Development, Applications Lead. Kim has her sights set on the future of PCR and is excited to see digital PCR grow more in the clinical market and become a new gold standard.

We had a fantastic time at today’s Genomics in Precision Oncology Xchange, where Stilla’s co-founder and Dir. of Business & Corp. Development Clément Gay gave the keynote: “Getting de-centralized testing into routine clinical oncology using high-performance genetic multiplexing.”

Are you familiar with Limit of Blank (LoB) and Limit of Detection (LoD)? Determining a false-positive cutoff when quantifying nucleic acids is critical to the robustness and reliability of a dPCR assay. Check out our technical note: bit.ly/3zXvOOJ

We’re feeling inspired after participating in the Bioserra LabCluster Tour with other innovative companies including our partner @promega. The Stilla team presented on high-multiplexing #digitalPCR tech in oncology—from clinical research to drug development to patient follow-up.